MedTrace Logo

Safety and Tolerability Study of Multiple Doses of PF-06305591

NCT01776619 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2013-12-03

No results posted yet for this study

Summary

Safety, tolerability and PK of repeated doses of PF-06305591 will be evaluated in young healthy volunteers toghether with food effect on relative bioavailability of solid formulation after single dose.

Conditions

  • Healthy

Interventions

DRUG

PF-06305591

14 day repeated 20mg BID doses

DRUG

Placebo

14 day repeated BID doses

DRUG

PF-06305591

14 day repeated 80mg BID doses

DRUG

Placebo

14 day repeated BID doses

DRUG

PF-06305591

14 day repeated 40mg BID doses

DRUG

Placebo

14 day repeated BID doses

DRUG

PF-06305591

14 day repeated BID doses

DRUG

PF-06305591

relative bioavailability tablet vs. solution and food effect at 50mg dose

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01776619 on ClinicalTrials.gov